Continuum Biosciences, Inc. is focused on improving how our bodies burn fuel. As we age, our metabolic rate declines and our bodies lose capacity for burning energy. This can result in excess nutrient storage and associated diseases including obesity, diabetes, fatty liver disease and other secondary conditions.
Scientists at Continuum have discovered new molecules that increase energy expenditure by targeting mitochondrial function. Continuum’s chemists are using multiple approaches to fine-tune the effectiveness and safety of their compounds for human use. These molecules have the potential to treat multiple diseases. Continuum is first targeting the fatty liver disease NASH.